Breaking News Instant updates and real-time market news.

INTC

Intel

$48.54

-0.78 (-1.58%)

, IMNP

Immune Pharmaceuticals

$0.00

(0.00%)

10:17
08/06/18
08/06
10:17
08/06/18
10:17

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Equal Weight from Overweight at Barclays with analyst Blayne Curtis saying he believes upside in the shares will be challenging until the company's margins bottom. 2. Immune Pharmaceuticals (IMNP) downgraded to Hold from Buy at Maxim with analyst Jason McCarthy citing the company's delisting from Nasdaq and evaluation of strategic options as it seeks to resolve its financing overhang. 3. Flowers Foods (FLO) downgraded to Equal Weight from Overweight at Consumer Edge. 4. CommScope (COMM) downgraded to Hold from Buy at Jefferies with analyst George Notter saying after "further reflection" from the earnings call and conversations with industry contacts, he believes CommScope's Mobility division performance will not improve this year or next. 5. Acadia (ACAD) downgraded to Neutral from Overweight at Piper Jaffray with analyst Danielle Brill saying the recent negative headlines related to potential Nuplazid safety issues will continue to weigh on sales and the shares for the foreseeable future. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

INTC

Intel

$48.54

-0.78 (-1.58%)

IMNP

Immune Pharmaceuticals

$0.00

(0.00%)

FLO

Flowers Foods

$20.97

-0.5 (-2.33%)

COMM

CommScope

$30.89

-0.75 (-2.37%)

ACAD

Acadia

$14.14

-1.09 (-7.16%)

  • 08

    Aug

  • 09

    Aug

  • 14

    Aug

  • 16

    Aug

  • 22

    Aug

  • 28

    Aug

  • 30

    Aug

  • 31

    Aug

INTC Intel
$48.54

-0.78 (-1.58%)

08/06/18
LEHM
08/06/18
DOWNGRADE
Target $53
LEHM
Equal Weight
Intel downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Blayne Curtis downgraded Intel to Equal Weight and cut his price target for the shares to $53 from $62. The analyst believes upside in the shares will be challenging until the company's margins bottom.
08/06/18
BOFA
08/06/18
NO CHANGE
Target $25
BOFA
Buy
AMD price target raised to $25 from $21 at BofA/Merrill
BofA/Merrill analyst Vivek Arya raised his price target on AMD (AMD) to $25 and kept his Buy rating while also raising his FY19 EPS target to 75c vs. consensus view of 62c. The analyst cites AMD's "generational opportunity" to exploit Intel (INTC) 10nm delays to gain market share data security and cloud servers along with its recent upward revision in server average selling prices, as indicated by Mercury industry data. Arya further notes the company's "discussion with several large cloud customers for its second-gen 7nm Rome server, as well as its 7nm computing graphics card for AI, where it competes against NVidia (NVDA).
08/06/18
LEHM
08/06/18
NO CHANGE
Target $15
LEHM
Underweight
AMD price target raised to $15 from $9 at Barclays
Barclays analyst Blayne Curtis raised his price target for (AMD) to $15 from $9 but keeps an Underweight rating on the name. The stock closed Friday down 30c to $18.49. The analyst this morning also downgraded his rating on Intel (INTC) to Equal Weight from Overweight. Curtis is now using a higher multiple for AMD to reflect a wider range of outcomes for traction of its Epyc server. The analyst, however, says he has not seen any evidence to support these more bullish levels. Clearly the market is much more optimistic on AMD's growth prospects as reflected in the stock's appreciation, Curtis tells investors in a research note. AMD has effectively reduced the discussion of future server performance to process technology but the lack of response from Intel following the multiple 10nm push-outs leaves little reason for investors to believe differently, Curtis writes.
08/06/18
LEHM
08/06/18
DOWNGRADE
Target $53
LEHM
Equal Weight
Barclays downgrades Intel to Equal Weight amid intensifying margin pressure
Barclays analyst Blayne Curtis downgraded Intel to Equal Weight from Overweight and cut his price target for the shares to $53 from $62. With both the server and personal computer markets outperforming, the debate on Intel shares has shifted to the competitive implications of the slippage in the company's process technology, Curtis tells investors in a research note titled "Hard to Defend in a Vacuum." Intel continues to believe that it can retain a performance advantage even with a process node disadvantage, but has provided little evidence to support this, the analyst adds. He believes this creates an "overhang well into 2019." Further, Curtis notes Intel's margin pressure will intensify next year. It is hard for the "stock to work" until the bottoms in margins is clearer, Curtis writes.
IMNP Immune Pharmaceuticals
$0.00

(0.00%)

08/06/18
MAXM
08/06/18
DOWNGRADE
MAXM
Hold
Immune Pharmaceuticals downgraded to Hold from Buy at Maxim
08/06/18
MAXM
08/06/18
DOWNGRADE
MAXM
Hold
Immune Pharmaceuticals downgraded to Hold from Buy at Maxim
Maxim analyst Jason McCarthy downgraded Immune Pharmaceuticals to Hold from Buy, citing the company's delisting from Nasdaq and evaluation of strategic options as it seeks to resolve its financing overhang. McCarthy notes that while he remains positive on Immune Pharmaceuticals' lead candidate drug bertilimumab and its previously demonstrated early positive data in bullous pemphigoid, he is moving to the sidelines while the company resolves its capital position challenges.
01/05/18
MAXM
01/05/18
INITIATION
Target $3
MAXM
Buy
Immune Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Jason McCarthy started Immune Pharmaceuticals with a Buy rating and Target $3, stating that he expects clinical trial enrollment to accelerate, more trials to initiate, and data points for bertilimumab to be realized in 2018.
FLO Flowers Foods
$20.97

-0.5 (-2.33%)

05/21/18
05/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hostess Brands (TWNK) initiated with a Buy at Berenberg while Flowers Foods (FLO) was initiated with a Hold. 2. Ceridian (CDAY) initiated with an Overweight at Piper Jaffray and MUFG, an Outperform at Wells Fargo, an Equal Weight at Barclays, a Neutral at JPMorgan and Goldman Sachs, a Market Perform at William Blair, as well as a Hold at Deutsche Bank, Canaccord, and Jefferies. 3. nLight (LASR) initiated with an Outperform at Raymond James as well as a Buy at Needham, Canaccord, Stifel, and DA Davidson. 4. VF Corp. (VFC) initiated with a Buy at Argus. 5. Chemours (CC) initiated with a Buy at Vertical Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/09/18
VERF
07/09/18
DOWNGRADE
VERF
Hold
Flowers Foods downgraded to Hold from Buy at Vertical Group
07/09/18
07/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy saying slowing market growth, volatility in emerging markets, U.S. retail difficulties, the stronger U.S. dollar and "pricing challenges" should drive estimates lower. 2. SeaWorld (SEAS) and Six Flags (SIX) were downgraded to Market Perform from Outperform at Wells Fargo. 3. Walgreens Boots Alliance (WBA) downgraded to Neutral from Buy at Citi with analyst Ralph Giacobbe saying he finds it difficult to argue for "meaningful multiple expansion" given headwinds from industry pressures and a dynamic and changing backdrop. 4. Flowers Foods (FLO) downgraded to Hold from Buy at Vertical Group. 5. Wayfair (W) downgraded to Market Perform from Outperform with the firm citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/06/18
CEDG
08/06/18
DOWNGRADE
CEDG
Equal Weight
Flowers Foods downgraded to Equal Weight from Overweight at Consumer Edge
COMM CommScope
$30.89

-0.75 (-2.37%)

08/06/18
JEFF
08/06/18
DOWNGRADE
Target $30.5
JEFF
Hold
CommScope downgraded to Hold from Buy at Jefferies
Jefferies analyst George Notter downgraded CommScope Holding to Hold and lowered his price target for the shares to $30.50 from $35.
08/06/18
JEFF
08/06/18
DOWNGRADE
Target $30.5
JEFF
Hold
CommScope downgraded to Hold with $30.50 price target at Jefferies
Jefferies analyst George Notter downgraded CommScope Holding to Hold from Buy and lowered his price target for the shares to $30.50 from $35. After "further reflection" from the earnings call and conversations with industry contacts, the analyst believes CommScope's Mobility division performance will not improve this year or next. Further, it is hard to see the business generating the kind of earnings power "required to make the stock interesting," Notter tells investors in a research note.
06/20/18
06/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tableau (DATA) initiated with a Neutral at Susquehanna. 2. Voya Financial (VOYA) reinstated with a Neutral at Goldman Sachs. 3. RBC Bearings (ROLL) initiated with a Hold at SunTrust. 4. Castlight Health (CSLT) initiated with an Outperform at William Blair. 5. CommScope (COMM) initiated with a Neutral at Rosenblatt. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/18
RSBL
06/20/18
INITIATION
Target $32
RSBL
Neutral
CommScope initiated with a Neutral at Rosenblatt
Rosenblatt analyst Ryan Koontz initiated CommScope with a Neutral rating and $32 price target, stating that the company's revenue outlook indicates modest share loss amidst declining gross margins and that he suspects the company has struggled with "mediocre" product innovation.
ACAD Acadia
$14.14

-1.09 (-7.16%)

04/26/18
JPMS
04/26/18
NO CHANGE
JPMS
Overweight
JPMorgan still sees low risk of Acadia drug being pulled from market
JPMorgan analyst Cory Kasimov continues to see a low, "but not zero," risk of Acadia Pharmaceuticals' Nuplazid being pulled from the market. Yesterday's CNN report is "mostly noise" and "nothing new," Kasimov told investors last night in a research note. The analyst, however, says he can appreciate the impact of the FDA Commissioner indicating he would "take another look" at the drug's safety profile. Kasimov predicates his views on the formal FDA review and the agency's initial statement that Nuplazid's safety profile is consistent with the label, as well as additional commentary he received yesterday from management. The analyst views yesterday's pullback in shares of Acadia as "fundamentally unjustified based on current information." He kept an Overweight rating on the stock. Shares of Acadia are up 5% to $15.95 in early trading.
04/10/18
COWN
04/10/18
NO CHANGE
Target $50
COWN
Outperform
Acadia pimavanserin concerns a reason for caution, says Cowen
Cowen analyst Ritu Baral noted yesterday's media report concerning deaths in the Acadia pimavanserin FAERS log. The analyst said based on conversations with key opinion leaders who have major experience with pimavanserin, she thinks there is unlikely a safety signal. However, she does say the concerns keep her cautious on the stock. Baral maintained her Outperform rating and $50 price target on Acadia shares, which dropped 23% to close at $16.50 yesterday.
04/10/18
JPMS
04/10/18
NO CHANGE
Target $50
JPMS
Overweight
Acadia sees little impact from CNN article, says JPMorgan
JPMorgan analyst Cory Kasimov says Acadia Pharmaceuticals management stressed to him their confidence that yesterday's CNN article would have little impact on Nuplazid's commercial prospects. Kasimov says that while management believes the news changes nothing, he worries "that the already tenuous sentiment around the name could have a difficult time withstanding this latest development." It remains to be seen what extent, if any, the creased scrutiny on the safety profile of Nuplazid negatively impacts the product's commercial outlook, Kasimov tells investors in a research note. He believes Acadia'a Q1 earnings report now has even greater significance. The analyst keeps an Overweight rating on Acadia with a $50 price target.
08/06/18
PIPR
08/06/18
DOWNGRADE
Target $19
PIPR
Neutral
Acadia downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill downgraded Acadia Pharmaceuticals to Neutral and cut her firm's price target for the shares to $19 from $61 after taking over coverage of the name. The stock closed Friday down 27c to $15.22. The recent negative headlines related to potential Nuplazid safety issues will continue to weigh on sales and the shares for the foreseeable future, Brill tells investors in a research note. Further, the analyst does not have a high level of conviction for positive data from Acadia's near-term catalysts, namely the Phase 2 major depressive disorder data in September and the Phase 2 negative schizophrenia symptoms readout in the first half of 2019.

TODAY'S FREE FLY STORIES

IFF

International Flavors

$122.54

-0.98 (-0.79%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
International Flavors rating change at Goldman Sachs »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

QRVO

Qorvo

$69.15

-0.93 (-1.33%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Qorvo rating change at Goldman Sachs »

Qorvo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

ATI

Allegheny Technologies

$26.02

0.065 (0.25%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Allegheny Technologies rating change at Goldman Sachs »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$4.98

0.17 (3.53%)

21:33
03/20/19
03/20
21:33
03/20/19
21:33
Upgrade
Internap rating change at Wells Fargo »

Internap upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$108.62

-1.79 (-1.62%)

, CAG

Conagra Brands

$22.91

0.095 (0.42%)

20:25
03/20/19
03/20
20:25
03/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.62

-1.79 (-1.62%)

CAG

Conagra Brands

$22.91

0.095 (0.42%)

CMC

Commercial Metals

$16.06

-0.06 (-0.37%)

GIII

G-III Apparel

$35.09

-0.475 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

HYMTF

Hyundai Motor

$0.00

(0.00%)

19:51
03/20/19
03/20
19:51
03/20/19
19:51
Periodicals
Hyundai shareholders to vote on Elliott Management dividend demand, Reuters says »

Hyundai Motor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVBF

CVB Financial

$21.12

-0.53 (-2.45%)

19:45
03/20/19
03/20
19:45
03/20/19
19:45
Hot Stocks
CVB Financial raises quarterly dividend to 18c from 14c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAMN

Kaman

$57.84

0.345 (0.60%)

19:24
03/20/19
03/20
19:24
03/20/19
19:24
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

Kaman is looking into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

VALE

Vale

$13.49

-0.21 (-1.53%)

19:19
03/20/19
03/20
19:19
03/20/19
19:19
Hot Stocks
Vale suspends operations at Alegria mine in Mariana complex on preventive basis »

Vale S.A. informs that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

EQH

AXA Equitable

$20.84

-0.565 (-2.64%)

19:12
03/20/19
03/20
19:12
03/20/19
19:12
Syndicate
AXA Equitable 40M share Secondary priced at $20.50 »

JPMorgan, Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

OTTW

Ottawa Bancorp

$13.56

-0.14 (-1.02%)

19:02
03/20/19
03/20
19:02
03/20/19
19:02
Hot Stocks
Ottawa Bancorp declares special dividend of 35c per share »

The special dividend will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$133.73

-1.74 (-1.28%)

18:57
03/20/19
03/20
18:57
03/20/19
18:57
Hot Stocks
Jazz Pharmaceuticals' Sunosi for excessive daytime sleepiness approved by FDA »

Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

AYI

Acuity Brands

$123.00

-5.53 (-4.30%)

18:52
03/20/19
03/20
18:52
03/20/19
18:52
Upgrade
Acuity Brands rating change at Goldman Sachs »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

HYAC

Haymaker Acquisition

$11.79

(0.00%)

, OSW

OneSpaWorld

$0.00

(0.00%)

18:47
03/20/19
03/20
18:47
03/20/19
18:47
Hot Stocks
OneSpaWorld says will start trading on Nasdaq March 21 »

OneSpaWorld Holdings…

HYAC

Haymaker Acquisition

$11.79

(0.00%)

OSW

OneSpaWorld

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

, MU

Micron

$40.08

-0.3 (-0.74%)

18:46
03/20/19
03/20
18:46
03/20/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

MU

Micron

$40.08

-0.3 (-0.74%)

WSM

Williams-Sonoma

$56.88

0.09 (0.16%)

SIEN

Sientra

$9.76

0.945 (10.73%)

EB

Eventbrite

$20.09

-0.72 (-3.46%)

GES

Guess

$22.10

-0.41 (-1.82%)

UNIT

Uniti Group

$10.01

0.15 (1.52%)

WEX

Wex

$184.85

-1.465 (-0.79%)

CBMG

Cellular Biomedicine

$18.26

0.38 (2.13%)

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

  • 21

    Mar

  • 21

    Mar

SAGE

Sage Therapeutics

$152.62

-3.46 (-2.22%)

18:39
03/20/19
03/20
18:39
03/20/19
18:39
Hot Stocks
Sage Therapeutics CEO: Postpartum depression is a medical issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$174.38

-1.39 (-0.79%)

18:27
03/20/19
03/20
18:27
03/20/19
18:27
Recommendations
Nvidia analyst commentary at Tigress Financial »

Nvidia to overcome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

18:24
03/20/19
03/20
18:24
03/20/19
18:24
Periodicals
CVS to start selling CBD products in partnership with Curaleaf, Bloomberg says »

Curaleaf (CURLF) said…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

PETQ

PetIQ

$29.87

0.91 (3.14%)

18:23
03/20/19
03/20
18:23
03/20/19
18:23
Hot Stocks
PetIQ CEO: We are totally transparent about our price model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

T

AT&T

$30.51

-0.19 (-0.62%)

18:21
03/20/19
03/20
18:21
03/20/19
18:21
Periodicals
AT&T CEO: Huawei makes it hard for carriers to shift suppliers, Reuters says »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

SGSOY

SGS SA

$0.00

(0.00%)

18:19
03/20/19
03/20
18:19
03/20/19
18:19
Downgrade
SGS SA rating change at Goldman Sachs »

SGS SA downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$155.94

-0.93 (-0.59%)

, RBGLY

Reckitt Benckiser

$0.00

(0.00%)

18:16
03/20/19
03/20
18:16
03/20/19
18:16
Hot Stocks
Clorox files false advertising lawsuit against Reckitt Benckiser »

The Clorox Company (CLX)…

CLX

Clorox

$155.94

-0.93 (-0.59%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BA

Boeing

$376.41

2.54 (0.68%)

18:09
03/20/19
03/20
18:09
03/20/19
18:09
Periodicals
Boeing pushes flight test to International Space Station to August, Reuters says »

Boeing has postponed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CE

Celanese

$101.04

0.08 (0.08%)

18:02
03/20/19
03/20
18:02
03/20/19
18:02
Hot Stocks
Celanese increases acetyl intermeditates prices »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

17:58
03/20/19
03/20
17:58
03/20/19
17:58
Syndicate
Frontdoor 16.73M share Secondary priced at $30.00 »

JPMorgan and Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.